Mutations that also confer resistance due to the impact on binding include Phe104lle located at the venetoclax binding site of BCL2 and Asp103Tyr, an essential part of hydrogen binding of venetoclax which have been identified in follicular lymphoma and CLL, respectively[15,16] [Table 2]. Here, BCL2 is linked to B-cell chronic lymphocytic leukemia.